
MHRAã¯éãã«ã7人ã«1äººãæ°åã³ããã®æ³šå°ã§éç¯€ãªæå®³äºè±¡ãçµéšãããšè¿°ã¹ãŠããŸã
å èšäºã¯ãã¡ããã/Click here to read the original article.
MHRA ãèšçœ®ããèœåçãµãŒãã€ã©ã³ã¹èšç»ã«ãããã¯ã¯ãã³å°å ¥ãã2幎以å ã«ã2人ã«1人ãæå®³äºè±¡ãçµéšãã7人ã«1äººãæ°åã³ããã®æ¥çš®åŸã«éç¯€ãªæå®³äºè±¡ãçµéšããããšã倿ããŸãããéç¯€ãªæå®³äºè±¡ã«ã¯ãé害ãå ¥é¢ãæ»äº¡ãå«ãŸããŸãã
2025幎12æãè±åœå»è¬åã»å»ç補åèŠå¶åºïŒMHRAïŒã«æåºãããã€ãšããŒã«ãŒãå ±åãæ€èšŒããç ç©¶ãDrug Safetyèªã«æ²èŒãããŸããã
ãImplementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory PerspectiveïŒè±åœã«ãããæ°åã³ãããŠã€ã«ã¹ææçãã³ãããã¯æã®èœåçã¯ã¯ãã³å®å šæ§ã¢ãã¿ãªã³ã°ã®å®æœãšçµæïŒèŠå¶åœå±ã®èŠç¹ïŒããšé¡ãããæ¬ç ç©¶ã¯ããYCVMãã©ãããã©ãŒã ã«ç»é²ããå人ã®ãããã£ãŒã«ãšããã®ããŒã¿ãã©ãããã©ãŒã äžã§æ°åã³ããã¯ã¯ãã³æ¥çš®åŸã«å ±åãããçãã®ããæå®³äºè±¡ãæ€èšãããããšãç®çãšããŠããŸããã
MHRAã®åœ¹å²ã説æãããããè«æã¯æ¬¡ã®ããã«è¿°ã¹ãŠããŸãããç ç©¶åœæãèè å šå¡ãè±åœä¿å¥ã»ç€ŸäŒçŠç¥çïŒDHSCïŒã®è¡æ¿æ©é¢ã§ããå»è¬åã»å»ç補åèŠå¶åºïŒMHRAïŒã«éçšãããŠããŸããâŠâŠMHRAã¯è±åœåžå Žã«ãããå»è¬åã®å®å šæ§ãç£èŠããæ³å®ã®è²¬åãè² ã£ãŠããŸããã
ç ç©¶ãææããŠããããã«ãã€ãšããŒã«ãŒãã»ã¯ã¯ãã³ã»ã¢ãã¿ãŒïŒYCVMïŒã¯ãæ°åã³ããã¯ã¯ãã³æ¥çš®åŸã®æå®³äºè±¡ãèœåçã«ç£èŠããããšãç®çã«MHRAã«ãã£ãŠèšç«ãããŸãããåå è ã®åéã¯2021幎ã«è¡ãããŸãããåå è ã¯YCVMãã©ãããã©ãŒã ã«èªäž»çã«ç»é²ããMHRAã«ããã¯ã¯ãã³å®å šæ§ã®èœåçãªã¢ãã¿ãªã³ã°ãåããŸããããã®ä»ã®å¥åº·é¢é£æ å ±ãšãšãã«ãåå è ã¯2020幎11æãã2022幎12æãŸã§ã®2幎éã«ããããMHRAã«æå®³äºè±¡ïŒå¯äœçšïŒãå ±åããŸããã
2025幎12æã®ç ç©¶ã§ã¯ãYCVMããã°ã©ã ã«å ±åãããæ°åã³ããã¯ã¯ãã³æ¥çš®åŸã®ãçãã®ããæå®³äºè±¡ããåæããŸããã察象ã¯36,604人ã§ããã®ãã¡30,281äººãæ°åã³ããã¯ã¯ãã³æ¥çš®ãåãããšå ±åããŠããŸãã
以äžã®åç»ã§ãã¢ã³ããªã¥ãŒã»ããªããžã§ã³ãæ¬ç ç©¶ã«ã€ããŠããã«èª¬æããŠããŸãã
ã2021幎ã«ãå»è¬åã»å»ç補åèŠå¶åºã¯âŠâŠçŽ36,000人ãåéãããã®ãã¡çŽ30,000人ãã³ããã®ã¯ã¯ãã³æ¥çš®ãåããŸãããããã«ã¯çŽ2,500人ã®åŠå©Šãšæä¹³äžã®å¥³æ§ãå«ãŸããŠããŸããããããŠåœŒãã¯4幎éããã®çµæãäŒããŠããã®ã§ãããšåœŒã¯è¿°ã¹ãŸããã
ãçµæã¯å³ãããã®ã§ããã
According to the MHRAâs own study data :-
â Andrew Bridgen (@ABridgen) April 21, 2026
51% of those who took the Covid jabs suffered a medical Adverse Event and 13.7% or 1 in 7 had a Severe Adverse event defined as :-
1. Death
2. Disability
3. Hospitalisation
4. Congenital defect
One in 7
When are the arrests starting ? pic.twitter.com/QYMtGFCmam
çµæã¯ïŒãã¯ã¯ãã³æ¥çš®ãå ±åãã人ã®ãã¡15,764人ïŒ52.1ïŒ ïŒãå°ãªããšã1ä»¶ã®æå®³åå¿ãçµéšãããšå ±åããŸãããããããã»ãšãã©ã¯æ³å®å ã®æ¥æ§åå¿ã§ããã4,134人ïŒ13.7ïŒ ïŒãå»åŠçã«é節ãšã¿ãªãããäºè±¡ãå ±åããŸãããã
52ïŒ ãæ¥æ§åå¿ãçµéšããã»ãŒ14ïŒ ãæ°åã³ããã¯ã¯ãã³æ¥çš®åŸã«ãå»åŠçã«é節ããŸãã¯éç¯€ãªæå®³äºè±¡ãçµéšããŸããã14ïŒ ã¯7人ã«1人ã«çžåœããŸãââ7人ã«1人ããäžèŠã«æ¥çš®ãããæ°åã³ããã¯ã¯ãã³ã«ãã£ãŠãå»åŠçã«é節ããªå®³ã被ã£ãã®ã§ãã
ããªããžã§ã³æ°ã説æããããã«ããéç¯€ãªæå®³äºè±¡ãšã¯ãæ»äº¡ãé害ãå ¥é¢ããããã¯æ°çå ã®å 倩æ§å¥åœ¢ã§ãâŠâŠã¯ã¯ãã³ã®å±é以éãè±åœã§æä¹ çãªéå®³ç¶æ ã«ãã人ã200äžäººå¢ããçç±ã¯ããã§èª¬æãã€ããšæããŸãâŠâŠãããä»ã§ãæå®³ãªæ³šå°ãæšãé²ããŠããã®ã§ããã
ç ç©¶ã®èè ã¯ãžã§ããŒã»ãŠã©ã³ïŒãJWãïŒããã£ãµãªã³ã»ããã¬ã³ïŒãKDãïŒãã±ã³ãã«ã»ããªãœã³ïŒãKHãïŒãã¿ãã©ã»ãžã£ã³ïŒãTJãïŒãã¢ãªãœã³ã»ã±ã€ãŽïŒãACãïŒããããŠãã£ã«ã»ãã¬ã°ã³ãïŒãPTãïŒã§ãããç ç©¶ã§ã¯èè ã®è²¢ç®ã次ã®ããã«èšèŒãããŠããŸãã
PTãKHãTJãKDã¯YCVMã®èšèšãšå®è£ ã«é¢äžããŸãããTJã¯æ¬ç ç©¶ã®ããã«YCVMãã©ãããã©ãŒã ããããŒã¿ãæœåºããŸãããJWã¯KDã®éèŠãªå©èšãåããŠããŒã¿ã®åæã宿œããŸãããå šèè ãããŒã¿è§£æã®è§£éã«é¢äžããŸãããåçš¿ã®åçš¿ã¯JWãšKDãå·çããŸãããå šèè ããã®åŸã®çš¿ãã¬ãã¥ãŒããå çããæçµçãæ¿èªããŸããã
Wong J, Donegan K, Harrison K, Jan T, Cave A, Tregunno P. Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective. Drug Saf. 2025 Dec;48(12):1365-1385. doi: 10.1007/s40264-025-01579-w. Epub 2025 Sep 3. PMID: 40900408; PMCID: PMC12605443. 以äžã®ãã€ãŒãã§ã¢ã³ããªã¥ãŒã»ã¯ãã±ãããææããããã«ãç ç©¶çµæã«ãããããã圌ãããããŒã¿ã¯å®å šæ§ã®æžå¿µã瀺ããªãã£ãããšå®£èšããŠããããããããã®èè ãšãã®è²¢ç®ã«ã€ããŠçæããŠããã¹ãã§ãã

ã¯ãã±ããã¯ããå®å šæ§ã«é¢ããæžå¿µã¯çããªãã£ãããšããèšè¿°ã®åŸã«ãå šäœãšããŠïŒoverallïŒããä»ãå ããŸããããããã¯æ£ç¢ºã§ã¯ãããŸãããç ç©¶ã§ã¯æ¬¡ã®ããã«è¿°ã¹ãããŠããŸãããåŠåš äžããã³æä¹³äžã®å¥³æ§ã«ãããŠãå®å šæ§ã«é¢ããæžå¿µã¯ããŒã¿ããã¯ç€ºãããªãã£ããæçµç°åžžã®å ±åã¯ãèªç¶çºççå ±åã·ã¹ãã ã§èŠãããããã«ãã¡ãã£ã¢ã®é¢å¿ã«ãã£ãŠåºæ¿ãããããã«èŠãããã
åŠåš äžããã³æä¹³äžã®å¥³æ§ã¯ãä»ã®äººéãšã¯å¥ã®çš®ã§ã¯ãããŸããããããã®å¥³æ§ã¯ãä»ã®äººã ãšåãé »åºŠã§ãåã害ããã¯ã¯ãã³ãããåããããšã«ãªããŸãããããŠãèªåã®èº«äœãããç¥ããæ¥çš®åŸã®å€åã«æ°ã¥ããã¡ãã£ã¢ã®ãé¢å¿ããé«ãŸãã¯ããåãããœãŒã·ã£ã«ã¡ãã£ã¢ã§èŠéã鳎ãããŠãã女æ§ãã¡ãããã¡ãã£ã¢ã®é¢å¿ã«ãã£ãŠåºæ¿ãããããšè¡šçŸããŠãããªãã¡å¿å æ§ã§ãããã®ããã«ç€ºåããŠã¬ã¹ã©ã€ãã£ã³ã°ããã®ã¯ãå¿ãŸãããããšã§ãã
ããèè ãããèå ããã³æä¹³äžã®åã©ãã«ãããŠå®å šæ§ã®æžå¿µãããŒã¿ããã¯ç€ºãããªãã£ãããšããæå³ã§ãã£ãã®ãªããYCVMããŒã¿ããŒã¹ã«ç»é²ããããããã£ãŠç 究察象ãšãªã£ã36,604人ã«å«ãŸããŠããèå ããã³æä¹³äžã®åã©ãã®æ°ã䜵ããŠèšèŒãã¹ãã§ããããããããæªæ¥çš®ã³ããŒãã®äžéšãšããŠå«ãŸããŠããã¯ãã§ãã